AbbVie's Dividend Looks Unpayable on Paper. The Cash Says Otherwise.

AbbVie's board declared a quarterly dividend of $1.73 per share on September 10, payable November 16 to shareholders on record as of October 15. On its face that is a board routine, not a headline: it is the same $1.73-per-share rate the company set when it raised the dividend in February, so this announcement adds no money. The only thing a routine declaration like this is useful for is forcing the question nobody asks about a company that always pays its dividend — is the payout actually covered, and by what?

That question is worth asking here, because how AbbVie's dividend looks depends entirely on which line of the income statement you choose to believe.

The 323% payout ratio that is not what it looks like

Pull up AbbVie's screen and the first thing that jumps out is a dividend payout ratio above 300%. A company paying out three dollars of dividends for every dollar it earns, on a trailing basis, is normally a company preparing either a cut or a capital raise. That is the reaction the number is designed to produce, and it is wrong.

The reason is mechanical, not suspicious. AbbVie has spent the past few years buying companies — ImmunoGen, Cerevel, and now a pending $10.9 billion deal for Apogee Therapeutics. When a drugmaker acquires a company, the price paid above the book value of its assets gets booked as an intangible that is then written off over time as amortization. That amortization is a huge, non-cash charge that runs straight through GAAP earnings and drags reported earnings down, even though no cash is leaving the business. The result is that AbbVie's reported earnings are far lower than its cash generation, and every earnings-based ratio built on them — payout ratio, P/E — looks alarming.

You can see the distortion directly. In the second quarter, AbbVie earned $3.65 a share on an adjusted basis, but only $2.03 under GAAP accounting, a gap driven by these non-cash charges. The reported P/E of roughly 100 is the same illusion on the valuation side; the cleanest earnings multiple, enterprise value to EBITDA, sits near 25, which is the sort of premium you pay for a quality pharma, not a troubled one.

What actually funds the dividend

So the test has to be cash flow, not accounting earnings. On that basis AbbVie's dividend is genuinely well covered. Free cash flow over the trailing twelve months was about $18.2 billion. The current dividend, at $1.73 four times a year across roughly 1.8 billion shares, costs the company a little over $12 billion a year. That works out to about one and a half dollars of cash flow for every dollar paid out — a cover ratio near 1.5×, exactly the kind of margin a dividend investor wants under an inflationary or investing-heavy year. On the guided adjusted earnings of roughly $14 a share for 2026, the payout sits near 50%, again comfortable.

The cash flow behind that dividend is also growing, and that is the part of the story worth paying attention to. AbbVie's problem was always the cliff: Humira, its former blockbuster, fell another 36% in the second quarter as biosimilars keep eating it. But the replacement is real. The immunology portfolio rose 15% in the quarter, led by Skyrizi, up 24% to $5.5 billion, and Rinvoq, up 25% to $2.5 billion — together far more than enough to offset Humira's decline and then some. Total revenue grew 10% to $16.99 billion in the quarter. This is a company whose cash flow is expanding while it pays out a growing dividend, which raises the dividend every year; it has done so in every year since its 2013 split-off, from $0.40 a quarter in 2014 to today's $1.73.

What you are paying for

The honest reservation is price. At $255, the stock yields about 2.6% on a forward basis. That is more than a money-market fund but well below the dividend yields on most large pharma peers — Pfizer sits near 6%, Bristol-Myers near 4% — precisely because the market is paying AbbVie a premium multiple for the growth and the reliability. You are buying a quality compounding business with a safe, growing income stream, and the lower starting yield is the price of that quality. Nothing about this dividend's structure is an accident or a distress signal; it is a deliberate, well-covered claim on cash flow that is being reinvested in growth.

For a retiree deciding whether this belongs in the income part of a portfolio, the gate is the same one a value investor would apply to any leveraged, payout-paying business: keep an eye on whether free cash flow keeps covering the dividend about one and a half times over while the company keeps funding deal-making and buybacks with debt. Net debt is about $64 billion and trailing free cash flow grew barely at all year over year — the accretion has come from the acquisitions themselves, not from expanding organic cash. So long as the cover holds, the dividend is a compounder's income, not a cigar butt. The moment deal-driven borrowing outruns cash generation, this safe-looking payout would deserve the scrutiny the 323% number invites. Today it earns a passing grade, because the test that matters is cash, and the cash says yes.